Anabolic Steroid Use and Aortic Dissection in Athletes: A Case Series.

Anabolic steroids Aortic Dissection Athletes

Journal

Oman medical journal
ISSN: 1999-768X
Titre abrégé: Oman Med J
Pays: Oman
ID NLM: 101526350

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 06 03 2019
accepted: 08 08 2019
entrez: 21 10 2020
pubmed: 22 10 2020
medline: 22 10 2020
Statut: epublish

Résumé

The use of anabolic steroids in supraphysiologic doses has grown in the last decade as doping drugs in athletes. The high dose of anabolic-androgenic steroids (AAS) causes cardiomyopathy, hypertension, thrombosis, myocardial infarction (MI), weakness of connective tissue, and its sequelae such as tendon injury and aortic dissection. Dissection of the ascending aorta is an uncommon injury that has been recognized with increasing frequency in bodybuilders in recent years. It has been proposed that such cases commonly accompany the weakening of connective tissue and must be actively evaluated in the presence of anabolic steroid usage. We present a case series of isolated ascending aorta dissection in athletes who were bodybuilders. All cases were evaluated by transthoracic echocardiography (TTE) and laboratory exams. These cases also served as a reminder of the risks of ascending aorta dissection with AAS, especially in strength athletes who place high demands on their musculoskeletal structures. The results of the current study suggested that anabolic steroid abuse may be associated with detrimental effects on the myocardium represented as cardiomyopathy or atherosclerotic changes in the coronary artery as MI. These findings also strongly suggest that anabolic steroid treatment predisposes the individual to aortic dissection, especially when the patients are exercised.

Identifiants

pubmed: 33083037
doi: 10.5001/omj.2020.120
pii: OMJ-35-05-1900052
pmc: PMC7568822
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e179

Informations de copyright

The OMJ is Published Bimonthly and Copyrighted 2020 by the OMSB.

Références

Vasc Health Risk Manag. 2008;4(6):1475-80
pubmed: 19337562
Eur J Clin Invest. 2009 Jan;39(1):31-6
pubmed: 19067736
Addict Health. 2009 Summer;1(1):25-9
pubmed: 24494079
Oman Med J. 2008 Apr;23(2):112-5
pubmed: 22379549
Curr Opin Investig Drugs. 2003 Oct;4(10):1213-9
pubmed: 14649214
Int J Legal Med. 2007 Jan;121(1):48-53
pubmed: 16292586
Atherosclerosis. 2019 Apr;283:100-105
pubmed: 30826541
Br J Sports Med. 2012 Nov;46 Suppl 1:i78-84
pubmed: 23097484
Angiology. 2008 Jun-Jul;59(3):376-8
pubmed: 18388062
Regul Toxicol Pharmacol. 2010 Jun;57(1):117-23
pubmed: 20153798
Sports Med. 2004;34(8):513-54
pubmed: 15248788
Histochem Cell Biol. 2005 Aug;124(2):167-75
pubmed: 16059740
Am J Sports Med. 2004 Mar;32(2):534-42
pubmed: 14977687
Sports Med. 2002;32(2):83-94
pubmed: 11817994
Int J Sports Phys Ther. 2015 Nov;10(6):748-59
pubmed: 26618057
J Sports Sci Med. 2006 Jun 01;5(2):182-93
pubmed: 24259990
Case Rep Cardiol. 2016;2016:6460386
pubmed: 27738530
Endothelium. 2006 May-Jun;13(3):227-31
pubmed: 16840178

Auteurs

Aghigh Heydari (A)

Cardiovascular Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Atefeh Asadmobini (A)

Cardiovascular Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Feridoun Sabzi (F)

Cardiovascular Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Classifications MeSH